FTC Weighs in On Improper Orange Book Patent Listings in Viatris-Sanofi Dispute

The FTC has filed an amicus brief amid the ongoing dispute between Viatris’ Mylan and Sanofi over the latter’s patents for Lantus insulin, assailing the use of improperly listed Orange Book patents to delay generic competition.
Source: Drug Industry Daily

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.